) enrolled the first patient in a phase III study (ESPART) on
Pergoveris. Merck KGaA is evaluating Pergoveris for
multifollicular development as part of an Assisted Reproductive
Technology (ART) treatment cycle in women classified as poor
ovarian responders (POR).
The multicenter, randomized, controlled, single-blind,
parallel Espart study is designed to assess the efficacy and
safety of Pergoveris in comparison with Gonal-f (used in the
treatment of infertility). The primary endpoint of the study is
the total number of retrieved oocytes. Ongoing pregnancy rate,
live birth rate, embryo implantation rate, clinical pregnancy
rate and biochemical pregnancy rate constitute the secondary
endpoints of the study.
As per the World Health Organization, over 72.4 million people
are affected by infertility globally and 15% of them resort to
Infertility is one of the main focus area of Merck KGaA's
largest division, Merck Serono. This study is part of Merck
KGaA's commitment toward achieving the shared goal of increasing
pregnancy rates and addressing the challenges to fertility.
Pergoveris is approved by the European commission/available in
the EU for the stimulation of follicular development in women
with severe luteinizing hormone (LH) and follicle stimulating
hormone (FSH) deficiency.
Merck Serono's revenues decreased 0.7% in 2013 due to currency
headwinds of 4.6%. Rebif sales grew organically by 1.4% in the
year. Gonal-f sales fell organically by 0.7% in 2013 due to an
adverse foreign exchange impact of 3.5%.
Merck KGaA carries a Zacks Rank #3 (Hold). Investors looking
for better-ranked stocks in the MEDICAL sector may consider
Salix Pharmaceuticals Ltd.
Lannett Co., Inc.
). Actavis carries a Zacks Rank #2 (Buy) while Lannett and Salix
carry a Zacks Rank #1 (Strong Buy).
ACTAVIS PLC (ACT): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
MERCK KGAA (MKGAF): Get Free Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.